[A17-18] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 19.10.2017
Project no.: A17-18
Commission: Commission awarded on 27.04.2017 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Moderate to severe rheumatoid arthritis in adult patients with insufficient response to prior treatment
For 4 questions added benefit not proven. In one subgroup (patients with unfavourable prognosis pretreated once, ≤ 65 years) hint of lesser benefit versus adalimumab)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.